Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sorin SpA announces CE mark approval for XL version of perceval sutureless aortic valve


Monday, 25 Nov 2013 04:20am EST 

Sorin SpA:Says it has received CE (ConformitĂ© EuropĂ©enne) Mark approval for the XL version of Perceval.Perceval is a bioprosthetic device designed to replace a diseased native or malfunctioning prosthetic aortic valve using either traditional or minimally invasive heart surgery. 

Company Quote

2.12
0.014 +0.66%
11 Jul 2014